Application of the ATN classification scheme in a population without dementia Findings from the EPAD cohort

Silvia Ingala, Casper De Boer, Larissa A Masselink, Ilaria Vergari, Luigi Lorenzini, Kaj Blennow, Gaël Chételat, Carol Di Perri, Michael Ewers, Wiesje M van der Flie, Nick C Fox, Juan Domingo Gispert, Sven Haller, José Luis Molinuevo, Graciela Muniz-Terrera, Henri JMM Mutsaerts, Craig W Ritchie, Karen Ritchie, Mark Schmidt, Adam J Schwarz, Lisa Vermunt, Adam D Waldman, Joanna Wardlaw, Alle Meije Wink, Robin Wol, Viktor Wottschel, Philip Scheltens, Pieter Jelle Visser, Frederik Barkhof, the EPAD consortium

Background: We classified non-demented European Prevention of Alzheimer’s Dementia (EPAD) participants through the amyloid/tau/neurodegeneration (ATN) scheme and assessed their neuropsychological and imaging profiles.

Materials and methods: From 1500 EPAD participants, 312 were excluded. Cerebrospinal fluid cut-offs of 1000 pg/mL for amyloid beta (Aβ1-42) and 27 pg/mL for p-tau181 were validated using Gaussian mixture models. Given strong correlation of p-tau and t-tau (R² = 0.98, P < 0.001), neurodegeneration was defined by age-adjusted hippocampal volume. Multinomial regressions were used to test whether neuropsychological tests and regional brain volumes could distinguish ATN stages.

Results: Age was 65 ± 7 years, with 58% females and 38% apolipoprotein E (APOE) ε4 carriers; 57.1% were A–T–N–, 32.5% were in the Alzheimer's disease (AD) continuum, and 10.4% suspected non-Alzheimer’s pathology. Age and cerebrovascular burden progressed with biomarker positivity (P < 0.001). Cognitive dysfunction appeared with T+. Paradoxically higher regional gray matter volumes were observed in A+T–N– compared to A–T–N– (P < 0.001).

Discussion: In non-demented individuals along the AD continuum, p-tau drives cognitive dysfunction. Memory and language domains are affected in the earliest stages.